Amyris Inc (NASDAQ:AMRS) was down 9.3% during trading on Tuesday . The company traded as low as $5.15 and last traded at $5.24. Approximately 811,394 shares changed hands during trading, an increase of 91% from the average daily volume of 424,651 shares. The stock had previously closed at $5.78.
A number of equities research analysts have commented on AMRS shares. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Amyris in a report on Thursday, January 18th. B. Riley started coverage on Amyris in a report on Thursday, January 25th. They set a “buy” rating and a $8.00 target price on the stock. ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, February 23rd. Zacks Investment Research cut Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, Cowen reiterated a “hold” rating and set a $4.00 target price on shares of Amyris in a report on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.69.
The company has a debt-to-equity ratio of -0.78, a quick ratio of 0.82 and a current ratio of 0.92.
Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in shares of Amyris by 16.3% during the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 4,603 shares during the last quarter. Carl Domino Inc acquired a new stake in shares of Amyris during the third quarter worth $182,000. Creative Planning acquired a new stake in shares of Amyris during the fourth quarter worth $188,000. KBC Group NV boosted its holdings in shares of Amyris by 228.4% during the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA boosted its holdings in shares of Amyris by 60.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares during the last quarter. Institutional investors and hedge funds own 22.71% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.